

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2013/058833 A8

(43) International Publication Date
25 April 2013 (25.04.2013)

(51) International Patent Classification:

A61K 39/00 (2006.01) *A61P 13/06* (2006.01)
A61K 38/00 (2006.01) *C12N 9/16* (2006.01)

(21) International Application Number:

PCT/US2012/039004

(22) International Filing Date:

22 May 2012 (22.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/549,047 19 October 2011 (19.10.2011) US
61/649,717 21 May 2012 (21.05.2012) US

(71) Applicants (for all designated States except US): **ENO-BIA CANADA LIMITED PARTNERSHIP** [CA/CA]; 2901 Rachel Street East, Suite 23, Montreal, Quebec, H1W 4A4 (CA). **VANDERBILT UNIVERSITY** [US/US]; 305 Kirkland Hall, Nashville, TN 37240 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CRINE, Philippe** [CA/CA]; 28 Avenue Claude-champagne, Outremont, Quebec, H2V 2X1 (CA). **ELEFTERIOU, Florent** [FR/US]; 4110 Westlawn Drive, Nashville, TN 37209 (US).

(74) Agents: **BIEKER-BRADY, Kristina** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

13 June 2013

(15) Information about Correction:

see Notice of 13 June 2013

(54) Title: COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF

(57) Abstract: The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. Polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndromes. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes.



WO 2013/058833 A8